Salim S Hayek, Sanja Sever, Yi-An Ko, Howard Trachtman, Mosaab Awad, Shikha Wadhwani, Mehmet M Altintas, Changli Wei, Anna L Hotton, Audrey L French, Laurence S Sperling, Stamatios Lerakis, Arshed A Quyyumi, Jochen Reiser
BACKGROUND: Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease. METHODS: We measured plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons...
November 12, 2015: New England Journal of Medicine